
- /
- Supported exchanges
- / US
- / ARGX.NASDAQ
argenx NV ADR (ARGX NASDAQ) stock market data APIs
argenx NV ADR Financial Data Overview
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get argenx NV ADR data using free add-ons & libraries
Get argenx NV ADR Fundamental Data
argenx NV ADR Fundamental data includes:
- Net Revenue: 2 643 M
- EBITDA: 191 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-15
- EPS/Forecast: -0.99
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
argenx NV ADR News

BofA Securities raises argenx stock price target to $829 on Vyvgart growth
Investing.com - BofA Securities raised its price target on argenx SE (NASDAQ:ARGX) to $829.00 from $804.00 while maintaining a Buy rating on the stock. The $34.8 billion market cap company has maintai...


Belgium stocks higher at close of trade; BEL 20 up 0.19%
Investing.com – Belgium stocks were higher after the close on Monday, as gains in the Healthcare, Utilities and Consumer Services sectors led shares higher. At the close in Brussels, the BEL 20 ros...

European Equities Traded in the US as ADRs Edge Up in Monday Trading
European equities traded in the US as American depositary receipts edged up Monday with the S&P Euro PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...

High Growth Tech Stocks in Europe with Promising Potential
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining relatively flat and major indexes like France's CAC 40 and Italy’s FTSE MIB posting m...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.